Kong Shum Smart Management Group (Holdings) Limited 港深智能管理集團（控股）有限公司 Kong Shum Smart Management Group (Holdings) Limited 港深智能管理集團（控股）有限公司 (incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司) Stock Code 股份代號：8181 (incorporated in the Cayman Islands with limited liability) (Formerly known as Shi Shi Services Limited 時 時時服務有限公司 時 服 務 有 限 公 司 ) 㾾 㾀 㠉 劌 䴰 䖕 KSSM INTERIM REPORT 2025/26 中期報告 (Stock Code: 8181) CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHA ...

CORPORATE INFORMATION 公司資料 | BOARD OF DIRECTORS | Mr. Yeung Him Kit, Dennis | 董事會 | 楊衍傑先生 | | --- | --- | --- | --- | | | (Chairman and Managing | | （主席兼董事總經理） | | | Director) | | | | | Madam Yeung Man Yee, Shirley | | 楊敏儀女士 | | | (Executive Director) | | （執行董事） | | | Mr. Lam Hing Lun, Alain | | 林慶麟先生 | | | (Finance Director) | | （財務董事） | | | Mr. Choi Man Chau, Michael | | 蔡文洲先生 | | | (Independent Non-executive | | （獨立非執行董事） | | | Director) | | | | | Mr. Sun Dai Hoe Harold | | 孫大豪先生 | | | (Independent Non-e ...

目錄 2 簡明綜合損益及其他全面收益表 3 簡明綜合財務狀況表 5 簡明綜合權益變動表 6 簡明綜合現金流量表 7 簡明綜合財務報表附註 17 管理層討論及分析 21 其他資料 簡明綜合損益及其他全面收益表 截至2025年9月30日止六個月 （以港元列示） | | | 截至9月30日止六個月 | | | --- | --- | --- | --- | | | | 2025年 | 2024年 | | | 附註 | 千港元 | 千港元 | | | | （未經審核） | （未經審核） | | 收益 | 4 | 45,045 | 44,622 | | 銷售成本 | 5 | (24,754) | (24,234) | | 毛利 | | 20,291 | 20,388 | | 其他收入 | | 5 | 56 | | 分階段收購一間附屬公司之收益 | 11 | – | 1,499 | | 銷售及分銷開支 | 5 | (8,798) | (7,136) | | 行政開支 | 5 | (10,334) | (10,908) | | 經營溢利 | | 1,164 | 3,899 | | 財務收入 | | 387 | 687 | ...

香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高 投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決 定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波 動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明， 並明確表示概不就因本報告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告包括的資料乃遵照聯交所的GEM證券上市規則（「GEM上市規則」）的規定而提供有關源想集團有限 公司（「本公司」）及其附屬公司（統稱「本集團」）的資料。本公司董事（「董事」）願就本報告共同及個別承擔 全部責任。董事在作出一切合理查詢後確認，就彼等所知及所信，本報告所載資料在各重大方面均屬準確 完整，且無誤導或欺騙成份，及本報告並無遺漏其他事項，致使本報告或當中所載任何陳述產生誤導。 1 源想集團有限公司 • 2025年中期報告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 GUANGDONG – HONG KONG GREATER BAY AREA HOLDINGS LIMITED 除2014年年報所載資料外，本公司董事（「董事」）會（「董事會」）謹此提供以下補 充資料。 根據上市規則附錄D2第24段（或當時上市規則附錄16），本公司謹此提供有關本 公司前任行政總裁王德文先生（「王先生」）截至2014年12月31日止年度薪酬的補 充資料。王德文先生於2014年5月13日獲委任為本公司行政總裁，於2015年1月 26日獲委任為本公司執行董事，並已於2022年辭任行政總裁及執行董事。 1 據董事作出一切合理查詢後所知、所悉及所信，王先生於截至2014年12月31日止 年度的薪酬如下： 以權益結算 薪金、津貼 退休計劃 以股份為基 粵港灣控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1396） 與截至2014年12月31日止年度的年度報告有關的補充公告 茲提述粵港 ...

Love The Community Serve The Better 服務美好 、善愛生活 Annual Report 2024 年報 Annual Report 2024 年報 OPERATION is the Key REPUTATION Comes First Service provider for the community and industry 社區運營服務商、產業運營服務商 BUSINESS MOTTO 經營理念 Surpassing Customers' Expectation and Creating Values with Quality Services 超越客戶期待、 服務創造價值 Leading Property Management Enterprise in the Yangtze River Delta Megalopolis 運營為王 口碑至上 長三角領先物管企業 BUSINESS MODEL 業務模式 Service alignment, Business modularisation, Modules specialisation and Management di ...

Serve The Better Love The Community 服務美好 、善愛生活 Interim Report 2024 中期報告 Interim Report 2024 中期報告 CONTENT 目錄 | 2 | Company Introduction | 28 | Interim Condensed Consolidated Statement | | --- | --- | --- | --- | | | 公司簡介 | | of Profit or Loss and Other Comprehensive Income | | | | | 中期簡明綜合損益及其他全面收益表 | | 3 | Corporate Information | | | | | 公司資料 | 30 | Interim Condensed Consolidated Statement of | | | | | Financial Position | | 5 | Management Discussion and Analysis | | 中期簡明綜合財務狀況表 | | | 管理層討論與分析 | | | | | | 3 ...

Revenue Performance - Medical products revenue for the fiscal year 2024 reached HKD 25.57 million, a 16.5% increase from HKD 21.94 million in fiscal year 2023[5] - Custom components for medical equipment saw a significant revenue increase of 86%, driven by a shift towards comprehensive systems like Continuous Glucose Monitoring (CGM)[8] - Sales of blood collection tubes and equipment dropped from HKD 30.43 million in fiscal year 2022 to HKD 14.13 million in fiscal year 2023, a decline of 53.6%[7] - Revenue from pandemic-related products fell to zero in fiscal year 2023, a 100% decrease from HKD 16.34 million in fiscal year 2022, due to normalized demand post-COVID-19[6] Product Development and Expansion - The company plans to expand its product offerings to include surgical instruments, orthopedic tools, imaging equipment, and disinfection products[11] - The company intends to launch 2 to 3 new co-developed products by 2026, including surgical instrument kits and imaging equipment accessories[14] - The newly obtained production license is a strategic expansion of the existing medical business segment, significantly broadening the product portfolio with new devices and components, including infusion and transfusion devices, nursing and care equipment, and protective gear[15] - The production license allows the company to market and sell a diverse range of medical devices in China, covering categories such as active and passive surgical instruments, orthopedic surgical instruments, medical imaging equipment, and more[16] Regulatory Compliance and Quality Control - The company is focusing on diversifying its product lines while ensuring regulatory compliance with certifications like CE and FDA[11] - The company emphasizes compliance with strict quality and regulatory standards to ensure the highest levels of safety and effectiveness for its medical products[28] - The production facilities have received FDA certification, reflecting the company's commitment to adhering to strict regulatory frameworks[28] - The company emphasizes strict quality control and regulatory compliance in all operations, whether internal or outsourced[30] Market Strategy and Partnerships - The company aims to achieve product registration and distribution permits in Shandong by August 2025, marking a significant milestone for market entry[12] - The company is actively seeking partnerships with subcontractors that have existing certifications to expedite market entry without significant capital expenditure[12] - The company anticipates obtaining additional provincial registrations in China by the fourth quarter of 2026 to expand its geographical coverage[13] - The company will adopt a data-driven regional expansion strategy to optimize service delivery and enhance commitment to hospital clients[34] Operational Capacity and Team - The company has established an 8-member dedicated operations team led by Mr. Dai Zhongliang, who has over ten years of experience in the medical products industry, to manage and monitor all manufacturing processes[27] - The company has a maximum annual production capacity of approximately 5 million units at its existing facility in Dongguan, China[31] - The business model under the production license remains unchanged, ensuring rapid expansion of the product range while maintaining effective operational strategies[17] Financial Projections and Market Outlook - The Chinese healthcare market is projected to grow at a compound annual growth rate of approximately 12-14%, reaching over $250 billion by 2030[32] - The company plans to achieve estimated sales of RMB 20 million by December 2025 through strategic partnerships with clients introduced by a new management team member[33] - The board is optimistic about business prospects due to strong market demand and strategic initiatives taken[32] - The establishment of a new subsidiary in Jinan, Shandong, aims to strengthen the company's market presence in China[33] Customer Engagement and Sales Strategy - The sales and marketing department is tasked with customer engagement, handling inquiries, and coordinating sales orders to ensure timely processing and delivery[23] - The company aims to enhance its core business by providing a more comprehensive product suite to meet broader customer needs and generate additional revenue streams[15] - The company will expand its customer base to include hospital clients, diversifying revenue sources and strengthening market position[33]

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性公告 關於 2021 年及 2022 年年報之補充公告 茲提述遠大醫藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）分別於 2022 年 4 月 25 日及 2023 年 4 月 27 日刊發之 2021 年年報及 2022 年年報（「年報」）。 除另有定義外，本函件所用之詞彙與年報所界定者具有相同涵義。 | | | | 退休福利 | | | --- | --- | --- | --- | --- | | | 袍金 | 薪金及津貼 | 計劃供款 | 合計 | | | 港幣千元 | 港幣千元 | 港幣千元 | 港幣千元 | | 執行董事： | | | | | | 劉程煒先生（於二零二一年六 | | | | | | 月一日退任） | 21 ...

SAM WOO CONSTRUCTION GROUP LIMITED 三和建築集團有限公司 中期報告 2025/26 2 三和建築集團有限公司（「本公司」）董事會（「董事會」）欣然呈列本公司及其附屬公司（統稱「本集 團」）截至2025年9月30日止六個月（「本期間」）的未經審核中期業績，連同2024年同期（「去年同 期」）的比較數字。該等資料應與截至2025年3月31日止年度的年度財務報表一併閱讀。 摘要 | | 2025/26上半年 | 2024/25上半年 | | --- | --- | --- | | 收入 | 470百萬港元 | 389百萬港元 | | 本期間溢利 | 47百萬港元 | 3百萬港元 | | 每股盈利 | 56.44港仙 | 3.85港仙 | | 中期股息 | 12港仙 | 無 | | | 2025年9月30日 | 2025年3月31日 | | 淨資產負債比率 | 14% | 28% | | 流動比率 | 0.95倍 | 0.87倍 | | 權益總額 | 527百萬港元 | 480百萬港元 | | 手頭主要合約總價值 （概約） | 630百萬港元 | 961百萬港元 | | | 尚未完成 ...